The new online face of BIOHIT

May 24, 2022


The launch of the new website coincides with an exciting time for BIOHIT, as the company moves to fulfil its vision of becoming a leading voice in digestive disease diagnosis, to empower healthcare providers and improve the lives of patients. The company’s strong portfolio has been created to address previously unmet needs of healthcare professionals working in this field, and enables the early diagnosis and prevention of gastrointestinal diseases. This range includes:

Graham Johnson, Managing Director of BIOHIT, said: “We are excited to showcase the fresh new look of our website, and look forward to welcoming many more online guests in the coming weeks and months. This update will make it far easier for our visitors to locate exactly what they need and learn about the crucial work that we do here at BIOHIT.”

For more information about BIOHIT product lines, browse

About BIOHIT HealthCare

BIOHIT HealthCare is a Finnish biotech company, headquartered in Helsinki, that specialises in the development, manufacture and distribution of kits and assays for the screening, diagnosis and monitoring of digestive diseases. Its core disease focus areas include stomach health and dyspepsia, reflux and acid dysregulation, Inflammatory Bowel Disease (IBD), functional gastrointestinal disorders (FGID), Irritable bowel syndrome (IBS), and gut microbiota dysbiosis. Innovating for Health

Recent Posts

Unboxing of Peptest

The inside edge on Peptest for the diagnosis of silent reflux

May 20, 2024
National Well-Being

The UK’s Health Landscape And The Endeavor For National Well-Being

May 10, 2024
Endoscopy in a hospital

Tackling the challenge of Helicobacter pylori in record time with the ULTRA-FAST UFT300 Quick Test

February 7, 2024

Exploring the value of biomarkers in gastric cancer screening

October 26, 2023